Vaccine List

Afluria is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.

ENGERIX-B is a vaccine indicated for immunization against infection caused by all known subtypes of hepatitis B virus.

FLUARIX QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUARIX QUADRIVALENT is approved for use in persons aged 3 years and older.

FLUCELVAX QUADRIVALENT is a vaccine that helps protect against influenza (flu). FLUCELVAX is for people aged 4 and older. Vaccination with FLUCELVAX QUADRIVALENT may not protect all people who receive the vaccine.

The Advisory Committee on Immunization Practices (ACIP) recommended that FluMist Quadrivalent not be used for the 2016-2017 season. FluMist Quadrivalent is a vaccine that is sprayed into the nose to help protect against influenza. It can be used in children, adolescents, and adults ages 2 through 49. FluMist Quadrivalent is similar to MedImmune’s trivalent influenza vaccine, except FluMist Quadrivalent provides protection against an additional influenza strain. FluMist Quadrivalent may not prevent influenza in everyone who gets vaccinated.

Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, and Fluzone High-Dose vaccines are given to help prevent influenza disease caused by influenza A and B strains contained in each vaccine. Fluzone Quadrivalent vaccine is given to people 6 months of age and older. Fluzone Intradermal Quadrivalent vaccine is given to people 18 through 64 years of age. Fluzone High-Dose vaccine is given to people 65 years of age and older.

Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, and Fluzone High-Dose vaccines are given to help prevent influenza disease caused by influenza A and B strains contained in each vaccine. Fluzone Intradermal Quadrivalent vaccine is given to people 18 through 64 years of age. How Is an Intradermal Flu Shot Different? Typical flu shots are intramuscular, which means they go through the skin, a layer of fat, and then the muscle. Intradermal vaccines are injected into the skin through a small, ultra-thin needle.3,4 And since the skin has more specialized immune cells than the muscle, the intradermal vaccine can provide a similar level of protection as the traditional flu shot.

GARDASIL is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16 and 18, Genital warts (condyloma acuminata) caused by HPV types 6 and 11  And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervical adenocarcinoma in situ (AIS);  Cervical intraepithelial neoplasia (CIN) grade 1; Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3; Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3

HARVONI is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C (Hep C) genotype (GT) 1, 4, 5 or 6 infection with or without cirrhosis (compensated). In those with GT 1 and advanced cirrhosis (decompensated) or with GT 1 or 4 with or without cirrhosis (compensated) who have had a liver transplant, HARVONI is used with ribavirin.

HepaGam B® [Hepatitis B Immune Globulin Intravenous (Human)] is an intravenous immune globulin indicated for the following: Prevention of Hepatitis B recurrence following liver transplant in HBsAg-positive liver transplant patients.  Post-exposure prophylaxis including: Acute exposure to HBsAg-positive blood, plasma, or serum (parenteral exposure, direct mucus membrane contact, oral ingestion, etc.), Perinatal exposure of infants born to HBsAg-positive mothers, Sexual exposure to HBsAg-positive persons, and Household exposure to persons with acute HBV infection.

Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.

MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.

PedvaxHIB is indicated for routine vaccination against invasive disease caused by Haemophilus influenzae type b in infants and children 2 to 71 months of age. PedvaxHIB should not be used in infants <6 weeks of age.

PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

ProQuad is a vaccine indicated for active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age.

RECOMBIVAX HB is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. RECOMBIVAX HB is approved for use in individuals of all ages. RECOMBIVAX HB Dialysis Formulation is approved for use in adult predialysis and dialysis patients 18 years of age and older.

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age.

Sanofi Pasteur confirms that YF-VAX® (Yellow Fever Vaccine) is unavailable to order in the U.S. until mid-2018 as the company transitions production to a new state-of-the-art facility, which is expected to occur in 2018. Sanofi Pasteur has worked with the FDA to make another yellow fever vaccine available in the US through an Expanded Access Investigational New Drug Application (IND). Manufactured by Sanofi Pasteur in France, this vaccine, STAMARIL® (Yellow Fever Vaccine [Live]), is registered and distributed in over 70 countries. However, it is considered investigational in the US, as it is not a US-licensed product. The Expanded Access Program has requirements similar to a clinical trial; thus Sanofi Pasteur can support only a limited number of sites. Working closely with the CDC, geographically distributed sites throughout the US were identified for inclusion in the program so patients can have continued access to yellow fever vaccine.

TRUVADA for PrEP (pre-exposure prophylaxis) is a prescription medicine that is used together with safer sex practices to help reduce the risk of getting HIV-1 through sex. This use is only for HIV-negative adults who are at high risk of getting HIV-1. To help determine your risk of getting HIV-1, talk openly with your healthcare provider about your sexual health.

TYPHIM Vi is a sterile solution, prepared from the purified polysaccharide capsule of Salmonella typhi (Ty 2 strain). The purified polysaccharide capsule is diluted in isotonic buffer solution which contains phenol as preservative. The vaccine is a clear, colourless solution. Each single dose of 0.5 mL is formulated to contain 0.025 milligrams of purified capsular polysaccharide, preserved with phenol (less than 1.25 mg per dose). The isotonic buffer solution contains 4.15 mg of sodium chloride, 0.065 mg of sodium phosphate dibasic dihydrate and 0.023 mg of sodium phosphate monobasic.

VARIVAX is a vaccine indicated for active immunization for the prevention of varicella (ChickenPox) in individuals 12 months of age or older. Each dose is approximately 0.5 mL after reconstitution and is administered by subcutaneous injection.

Vaxchora is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected areas.

YF-VAX is indicated for active immunization for the prevention of yellow fever in persons 9 months of age and older in the following categories: Persons Living in or Traveling to Endemic Areas, Persons Travelling Internationally Through Countries with Yellow Fever, Laboratory Personnel